Skip to main content

Table 2 Studies of PCOS and endometrial cancer risk

From: Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review

Author

Year

Study design

Endometrial Cancer Cases (n)

Overall result RR (95% CI)

Gottschau

2015

Registry cohort (Denmark)

16

3.9 (2.2–6.3)a

Shen

2015

Registry cohort (Taiwan)

7

4.7 (1.6–14.1)a

Barryb

2014

Meta-analysis

1264

2.8 (1.3–6.0)a

Haoulac

2012

Meta-analysis

938

2.9 (1.5–5.5)a

Brintond

2010

Cohort (US)

15

2.0 (1.1–3.3)a

Fearnleye

2010

Case control (Australia)

156

2.2 (0.9–5.7)

Chittendenf

2009

Meta-analysis

667

2.7 (1.0–7.3)c

Zucchetto

2009

Case–control (Italy)

454

1.3 (0.7–2.2)

Iatrakise

2006

Case–control (Greece)

81

9.0 (0.5–176.0)a,g

Pillayh

2006

Cross-sectional (UK)

128

1.0 (0.4–2.7)a,c

Niwa

2000

Case–control (Japan)

136

8.9 (0.4–184.9)a,g

Wild

2000

Cohort (UK)

11

6.1 (1.0–36.9)

Escobedo

1991

Case–control (US)

437

5.4 (2.4–12.3)a

Coulami

1983

Cohort (US)

5

3.1 (1.1–7.3)a

  1. a Effect estimate not adjusted for BMI
  2. b This meta-analysis includes the studies by Fearnley, Zucchetto, Iatrakis, Niwa, and Escobedo
  3. c This meta-analysis includes the studies by Fearnley, Iatrakis, Pillay, Niwa, and Escobedo
  4. d In this study, androgen excess or menstrual disorders was evaluated rather than PCOS
  5. e This study only included women less than 50 years old
  6. f This meta-analysis includes the studies by Iatrakis, Pillay, Niwa, and Escobedo
  7. g Odds ratio was calculated based on numbers provided in the paper
  8. h In this study, polycystic ovary morphology was evaluated rather than PCOS
  9. i In this study, chronic anovulation syndrome was evaluated rather than PCOS